REG - Medpal AI PLC - Result of WRAP Retail Offer

Medpal AIAnnouncement

02/10/2025 08:15

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251002:nRSB8079Ba&default-theme=true

RNS Number : 8079B  Medpal AI PLC  02 October 2025

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE
OR IN PART, OR INTO OR WITHIN THE UNITED STATES, AUSTRALIA, NEW ZEALAND,
CANADA, SOUTH AFRICA OR JAPAN, OR ANY MEMBER STATE OF THE EEA, OR ANY OTHER
JURISDICTION WHERE, OR TO ANY OTHER PERSON TO WHOM, TO DO SO MIGHT CONSTITUTE
A VIOLATION OR BREACH OF ANY APPLICABLE LAW OR REGULATION. PLEASE SEE THE
IMPORTANT NOTICE AT THE END OF THIS ANNOUNCEMENT.

 

2 October 2025

 

MedPal AI Plc

("MedPal AI" or the "Company")

 

Result of Placing and WRAP Retail Offer

 

Further to its announcements made on 1 October 2025 (the "Launch
Announcements"), MedPal AI plc is pleased to announce the successful
completion of the Placing and WRAP Retail Offer (together, the "Fundraise"),
at the Issue Price of 8 pence per share.

The Fundraise has raised, in aggregate, gross proceeds of approximately
£545,304 comprising  £400,000 pursuant to the Placing and £145,304
pursuant to the WRAP Retail Offer. Accordingly, the Company will issue
6,816,305 new ordinary shares ("New Ordinary Shares") to investors in the
Fundraise.

The proceeds of the Fundraise will be  used to progress the Company's
strategy with regard to the recently announced acquisition of assets from
Universal Pharmacy Ltd (in administration), which will enable MedPal AI to
establish itself in the rapidly growing GLP-1 agonist market for obesity
treatment, including drugs such as semaglutide (eg. Ozempic and Mounjaro).

 

Settlement of the New Ordinary Shares and Admission are expected to take place
on or around 8.00 a.m. on 8 October 2025. The Fundraise is conditional upon,
among other things, Admission (as defined below) becoming effective.

 

Admission and Total Voting Rights

Application has been made for the 6,816,305  New Ordinary Shares to be
admitted to trading on AIM on or around 8 October 2025 ("Admission"). The New
Ordinary Shares will rank pari passu with the Ordinary Shares of the Company
in issue.

Following Admission, the Company's issued share capital will comprise
419,899,640 Ordinary Shares of 0.02p each, with each share carrying the right
to one vote, therefore the total number of voting rights in the Company will
be 419,899,640. This figure may be used by shareholders as the denominator for
calculations by which they will determine if they are required to notify their
interest in the Company, or a change to their interest in the Company, under
the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.

 

Capitalised terms used in this announcement have the meanings given to them in
the Launch Announcements, unless the context provides otherwise.

 

This announcement contains inside information for the purposes of Article 7 of
EU Regulation 596/2014 (which forms part of domestic UK law pursuant to the
European Union (Withdrawal) Act 2018). The Directors of the Company are
responsible for the contents of this announcement.

 

 

 

 MedPal AI plc                       www.medpalplc.com (https://www.medpalplc.com/)

 Jason Drummond

 Cairn Financial Advisers LLP        +44 20 7213 0880

 Louise O'Driscoll/Jo Turner

 Clear Capital Markets Limited       +44(0) 20 3869 6080

 Bob Roberts

 Winterflood Retail Access Platform  WRAP@winterflood.com

 Sophia Bechev, Kaitlan Billings     +44(0) 20 3100 0214

 

Further information on the Company can be found on its website at
www.medpalplc.com

 

 

 

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  ROIMTBRTMTMMMBA